New antibody drug for blood cancers tested in first human trial
NCT ID NCT05263739
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This was a very early (phase 1) study testing a new antibody drug called ESG206 in people with advanced B-cell blood cancers that had stopped responding to other treatments. The main goal was to check safety and find the right dose. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ESG206 (an antibody drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for certain blood cancers that have not responded to standard therapies.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data exists. Even if it had started, phase 1 trials are very early and most drugs do not prove effective or safe enough to move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.